Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi Abandons Multiple Mid-Stage Drug Programs

As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.

Read More »

Biogen stops testing Tysabri to treat stroke after study fails

Biogen Inc. will stop testing the company’s established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study.

Read More »

High blood pressure in pregnancy may not disappear afterward

Women who develop high blood pressure during pregnancy may have the condition reappear within a year of delivery, and many of them may go undiagnosed because the problem only surfaces at night, a new study suggests.

Read More »

Xtandi delays prostate cancer spread in early-stage disease

Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.

Read More »

Genentech’s Tecentriq and Avastin combo met co-primary endpoint in late-stage study for advanced kidney cancer

Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.

Read More »

Three Small CRISPR Biotechs That Could Cure 10,000 Diseases

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.

Read More »

Bristol-Myers’ Lung Cancer Combo Wows in Phase III

Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.

Read More »

EyeGate’s Eye Drug Fails Phase II Test

EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.

Read More »

Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015

Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.

Read More »

Anika Therapeutics Announces Strategic Collaboration

Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom